Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: Immune checkpoint inhibitors (ICIs) are the preferred treatments for advanced non-small cell lung cancer (NSCLC) without targetable oncogene alterations. However, evidence in the elderly population (aged ≥ 65 years) remains limited.
Methods: We searched PubMed, Embase, Cochrane Library, Web of Science, and Scopus databases for eligible publications until September 30, 2024. The primary outcome of interest was overall survival (OS). A random-effects model was used for the statistical analysis.
Findings: A total of 35 phase 3 randomized controlled trials (RCTs) involving 9788 patients and 64 real-world studies involving 37,111 patients were included. Results from phase 3 RCTs revealed that ICIs significantly improved OS (hazard ratio [HR] = 0.78, 95% confidence interval [CI]: 0.74-0.82) and progression-free survival (PFS) (HR = 0.67, 95% CI: 0.60-0.75) compared to chemotherapy. The association between ICIs and improved OS was independent of patient characteristics (race and histological type) or treatment-related factors (ICI drug type, treatment mode, and treatment line). However, significantly prolonged OS was not observed in subgroups of aged ≥ 75 years and PD-L1 < 1%. In real-world studies, the pooled median OS of ICIs were 11.8 months (95% CI: 11.2-12.4); Eastern Cooperative Oncology Group (EOCG) score, histological type, PD-L1 status, with immune-related adverse events (irAEs), and treatment mode were predictive for OS; rates of irAEs and discontinuation were numerically higher for combination therapy vs. monotherapy.
Interpretation: ICIs are associated with a significant improvement in OS and PFS compared to chemotherapy in elderly patients with advanced NSCLC. Nevertheless, some patient characteristics such as aged ≥ 75 years, ECOG score ≥ 2, and PD-L1 < 1% seem to have a negative impact on the efficacy of ICIs, while these findings require further validation in large RCTs.
Funding: None.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11836518 | PMC |
| http://dx.doi.org/10.1016/j.eclinm.2025.103081 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Syllable-based speech characteristics as potential biomarker for differential diagnosis of Parkinson's disease, multiple system atrophy, and cerebellar ataxia.
J Neurol
September 2025
Department of Neurology, Seoul National University Hospital and Seoul National University College of Medicine, 101 Daehakro Jongno-gu, Seoul, 03080, Republic of Korea.
Speech disorders differ between Parkinson's disease (PD) and multiple system atrophy (MSA), but studies focusing on group differences based on syllables or including cerebellar ataxia (CA) are lacking until now. This cross-sectional study aimed to analyze syllable-based speech characteristics in patients with PD, MSA, and CA, as well as healthy controls, to determine their diagnostic utility. Speech samples were collected from 68 PD, 52 MSA, 23 CA, and 70 healthy controls.
View Article and Find Full Text PDFAssociation of patient and physician characteristics with androgen-deprivation-therapy intensification in patients with de novo hormone-sensitive metastatic prostate cancer: A population-based study.
Cancer
September 2025
Division of Urology, Department of Surgery, University of Toronto, Toronto, Ontario, Canada.
Introduction: Treatment intensification with androgen receptor signaling inhibitors and/or chemotherapy is guideline recommended for patients with de novo metastatic hormone-sensitive prostate cancer (mHSPC). However, most patients only receive androgen deprivation therapy monotherapy. The aim was to identify physician-, patient-, and tumor-related factors associated with the receipt of treatment intensification.
View Article and Find Full Text PDFAutomated quantification of abdominal aortic calcification using 3D nnU-Net: a novel approach to assess AAA rupture risk.
BMC Med Imaging
September 2025
Division of Vascular and Interventional Radiology, Department of General Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong Province, 510515, China.
Background: Abdominal aortic aneurysms (AAA) pose a serious rupture risk, heightened by aortic calcification. Traditional calcification scoring methods are slow and require expertise. This study aims to construct a convolutional neural network (nnU-Net) model for automatic quantification and segmentation of abdominal aortic calcification from a single CTA scan.
View Article and Find Full Text PDFOptimizing the water drinking test: evaluating the reproducibility and validity of a shortened protocol: a randomized prospective trial.
Int Ophthalmol
September 2025
Department of Ophthalmology, Faculty of Health Sciences, Samson Assuta Ashdod Hospital, Ben-Gurion University of the Negev, Ashdod, Israel.
Purpose: This study aimed to evaluate a a shortened Water drinking test (WDT) protocol and explore potential factors of patient characteristics such as body mass index (BMI) or Body Surface Area (BSA).
Methods: This was a prospective, randomized study comparing two validated WDT dosage regimens: 10 mL/kg and a fixed 800 mL intake. Patients were randomly assigned to one of the two groups.
Vinorelbine With or Without Thiotepa for HER2-Negative Metastatic Breast Cancer: A Propensity Score Analysis.
Cancer Med
August 2025
Department of Medical Oncology, Sorbonne Université, Assistance Publique-Hôpitaux de Paris (AP-HP), Institut Universitaire de Cancérologie, CLIP2 Galilée, Pitié-Salpêtrière Hospital, Paris, France.
Background: Vinorelbine is commonly used to treat metastatic breast cancer (mBC), while thiotepa is known for its ability to cross the blood-brain barrier.
Methods: Our retrospective study aimed to compare the efficacy and safety of vinorelbine with or without thiotepa in patients with HER2-negative mBC. We used propensity score inverse probability of treatment weighting to ensure comparability between groups.